• Website-banner-v2

Fondo Azionario Euro


    Diversifying between different share classes is becoming increasingly important. Equities are becoming more and more attractive. The Euro Equity Fund aims to achieve a higher level of return for investors by investing primarily in a diversified portfolio of blue-chip stocks (eg equities). The Euro Equity Fund invests in Blue Chip companies dealt with on the main European markets. The Blue Chip companies are known to be better at moments of recession and operate in profit even in negative economic conditions. An excellent reputation for stable and reliable growth.


    The Fund is administered according to the structure of the UCITS, which has become the standard for investment funds in the EU, for retail investors. The UCITS Funds are ideal for retail investors, as well as for the provision of diversification and liquidity through specific parameters.


    The funds are managed by a group of professional investors at Calamatta Cuschieri Investment Management Ltd, who monitor their developments on a daily basis.

  • Related Downloads


→ Profilo dell'investitore
→ Valute
→ Integrazioni
→ Monitoraggio e Prezzo
→ Commissioni di Ingresso e Uscita
→ Investimento minimo
→ Regolamento del Fondo in Sintesi
→ Obiettivo sul Dividendo
→ Altre Informazioni


May 2020 Commentary

The rebound in equity markets extended into May. The impact of the COVID-19 pandemic continued to dominate markets, with an increasing focus on how countries would begin to relax their lockdown measures and how this would affect the economy. Volatility declined and the more moderate market moves compared to April suggest that investors are being watchful of how the situation develops.

Many countries began some level of reopening. The S&P 500 climbed to end the month 4.8% higher and is now just 10% below the February peak. The infection rate across the major European economies has fallen significantly, though the infection rate in the UK still remains high relative to its European peers. Many states in the US began some level of reopening, though the daily infection rate has only fallen to around 65% of the peak infection rate from mid-April.

Investors appeared to become somewhat more optimistic about the outlook after initial signs of success in human trials of a vaccine against COVID-19. Growth stocks outperformed value stocks while global government bond markets were broadly flat. European and Japanese stock markets, typically cyclical markets, also ended the month higher. Despite the first steps being taken to exit lockdown and some positive news on a potential vaccine, it’s still too early to say with confidence how the public health outlook will evolve.

Despite May’s market rebound, considerable uncertainty remains over the trajectory of global growth over the coming quarters. A lot will depend on the extent to which economies can successfully reopen. For this reason, the investment managers remain prudent and expect further volatility. However, they acknowledge that the unprecedented policy response – particularly the willingness of central banks to intervene in credit markets – has shifted the balance of risks.


  • NAV/Prezzo: Clicca qui per Prezzi aggiornati

    Nome del Comparto Euro Equity Fund
    Investment Manager Calamatta Cuschieri Investment Management Ltd
    Conculente del Fondo n/a
    Depositario Sparkasse Bank Malta p.l.c.
    Amministratore del Fondo CC Fund Services (Malta) Limited.
    Revisori Deloitte Malta
    Consulente Legale Ganado & Associates
    Data di Lancio 1st November 2013
    Sede Malta
    Valuta Euro (€)
    Frequenza Negoziazioni Daily
    Dimensione Fondo €7.0 M
    Numero di Titoli 23
    Commissione Iniziale up to 2.5%
    Tassa di Gestione 1.35%
    Data pagamento Dividendo N/A
    Numero ISIN EUR – MT7000009031
    Minimum Initial Investment € 2,500
    Minimum Additional Investment € 500

    Country Exposure*

    Country %
    Germany 44.7
    United States 16.4
    Malta 15.3
    France 14.7
    Netherlands 4.2
    Austria 0.0

    *including exposures to ETFs

    Top Equities

    Equity %
    L’ OREAL 5.2
    Amazon inc 5.2
    Microsoft Corp 4.8
    Alibaba Group 4.2
    ASML NV 4.2
    Mastercard 3.9
    Sanofi 3.7
    Home Depot inc. 3.2
    SAP SE 3.2


    Top ETFs

    ETF %
    iShares Eurostoxx 50 De 8.8
    iShares MSCI World Min Vol 8.4
    Lyxor EuroStoxx600 Technology 7.1
    Lyxor EuroStoxx600 Healthcare 5.9
    Lyxor DAX DR 2.9


  • Performance ad Oggi (EUR)

    Performance History

    Calendar Year Performance YTD 2019 2018 2017 Since
    Total Return -9.06 27.49 -18.36 10.39 11.92
    Calendar Year Performance 1-   month 3-    month 6-   month 9-   month 12-    month
    Total Return 2.08 -1.64 -7.87 0.13 3.95

    * The Euro Equity Fund was launched on 31 October 2013.

    Currency Allocation

    Currency %
    EUR 86.2
    USD 13.8
    GBP 0.0

    Asset Allocation

    Asset %
    Cash 10.4
    Equities 89.6

    Sector Breakdown

    Sector %
    ETFs 37.0
    Technology 14.6
    Consumer, Non-Cyclical 11.6
    Financial 10.1
    Communications 10.0
    Consumer, Cyclical   4.8
    Industrial   1.5


Informazioni Legali

* The Fund achieved a performance increase of 10.92% during the period 1st November 2013- 31st October 2015 (Source: Calamatta Cuschieri Fund Services). Calamatta Cuschieri Investment Services (CCIS) is a founding member of the Malta stock exchange and is licensed to conduct Investment Services in Malta by the Malta Financial Services Authority. The CC Euro Equity Fund is a sub fund of  CCFunds Sicav plc and is authorised by the MFSA. Performance figures quoted refer to the past and are not a guarantee for future performance. The value of the investment may rise as well as fall. Investors may incur a subscription charge and may be subject to tax on distributions. Investment should be based on the CCFunds Sicav plc prospectus and KIID document, which may be obtained from CCIS offices. Issued by CCIS. 
This document is prepared for information purposes only and should not be interpreted as investment advice. This document does not constitute an offer or invitation by CCIS to any person to buy or sell any investment. CCIS has based this document on information obtained from sources it believes to be reliable but which have not been independently verified. This document may not be reproduced either in whole, or in part, without the written permission of CCIS.